Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study

dc.creatorLuetkemeyer, Anne F.
dc.creatorRosenkranz, Susan L.
dc.creatorLu, Darlene
dc.creatorGrinsztejn, Beatriz
dc.creatorSanchez, Jorge
dc.creatorSsemmanda, Michael
dc.creatorSanne, Ian
dc.creatorMcIlleron, Helen
dc.creatorHavlir, Diane V.
dc.creatorHaas, David W.
dc.date2018-10-11T18:27:44Z
dc.date2018-10-11T18:27:44Z
dc.date2015
dc.date.accessioned2023-09-27T00:12:36Z
dc.date.available2023-09-27T00:12:36Z
dc.identifierLUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860-1863, 2015.
dc.identifier1058-4838
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/29549
dc.identifier10.1093/cid/civ155
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898549
dc.descriptionIn STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
dc.description2028-08-30
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectHIV/AIDS
dc.subjectEfavirenz
dc.subjectPharmacogenetic
dc.subjectRifampin
dc.subjectTuberculosis
dc.subjectAdult AIDS Clinical Trials Group A5221 Study Team
dc.subjectA5243 Study Team
dc.titleCombined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study
dc.typeArticle


Este ítem pertenece a la siguiente institución